Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT PARENTS: Reducing NICU S. aureus Transmission
NCT02223520Completed
- Sponsor
- Johns Hopkins University
- Start
- Nov 2014
- Primary completion
- Oct 2019
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Staphylococcus aureus colonization comparing Mupirocin + Chlorhexidine with Placebo (2 arms). Primary endpoint: Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain at 90 days. Started Nov 2014; status: completed.
02
Drugs
mupirocinchlorhexidine + cymenol gel
03
Conditions
Staphylococcus aureus colonization
Beyond the preview
Go deeper on NCT02223520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223520.